Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers
This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer. The meeting opened with an overview of DNA repair and the biological basis for targeting this process in oncology, d...
Main Authors: | Tristin Abair, Hilary Calvert, Nicoletta Colombo, Eric Pujade-Lauraine, Andrew Tutt, Eric Van Cutsem |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2015-11-01
|
Series: | European Medical Journal Oncology |
Subjects: | |
Online Access: | http://emjreviews.com/wp-content/uploads/Incorporating-PARP-Inhibition-in-Cancer-Therapy-Key-Questions-Expert-Answers.pdf |
Similar Items
-
Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR)
by: Toni Choueiri
Published: (2015-11-01) -
Intelligent Application of Breast Cancer Trials Data in the Clinic
by: Joanne Frankli, et al.
Published: (2015-11-01) -
Evidence-based treatment planning in mCRC- The key to maximising outcomes
by: Dirk Arnold, et al.
Published: (2013-10-01) -
Answering Pivotal Questions in the Diagnosis and Treatment of Primary Biliary Cirrhosis and Non-Alcoholic Steatohepatitis
by: Michael Trauner, et al.
Published: (2015-06-01) -
International Evidence on Effective Early Childhood Care and Education Programs: A Review of Best Practices
by: Giselle Emilia Navarro-Cruz, et al.
Published: (2018-07-01)